Diagnosis and treatment of Parkinson disease: Molecules to medicine

Journal of Clinical Investigation

Volumn 116, Issue 7, 2006, Pages 1744-1754

  Savitt, Joseph M ^a   Dawson, Valina L ^a   Dawson, Ted M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2 RECEPTOR ANTAGONIST; ALPHA SYNUCLEIN; ANTIEMETIC AGENT; ANTIOXIDANT; APOMORPHINE; BENSERAZIDE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CREATINE; DECARBOXYLASE INHIBITOR; DJ 1 PROTEIN; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DUODOPA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; ISTRADEFYLLINE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MINOCYCLINE; MONOAMINE OXIDASE B INHIBITOR; PARKIN; PHOSPHOTRANSFERASE; PRAMIPEXOLE; PROTEIN PINK 1; RASAGILINE; ROPINEROLE; ROTIGOTINE; SARIZOTAN; SELEGILINE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

BRAIN DEPTH STIMULATION; CELL DEATH; CLINICAL TRIAL; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DYSKINESIA; GAIT DISORDER; GENETIC ASSOCIATION; HUMAN; META ANALYSIS; MITOCHONDRION; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PALLIATIVE THERAPY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; RIGIDITY; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREMOR;

ALPHA-SYNUCLEIN; DISEASE PROGRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; ONCOGENE PROTEINS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

EID: 33745847479     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29178     Document Type: Review

References (125)

1. Nutt, J.G., and Wooten, G.F. 2005. Clinical practice. Diagnosis and initial management of Parkinson's disease. N. Engl. J. Med. 353:1021-1027.
2. Elbaz, A., et al. 2002. Risk tables for parkinsonism and Parkinson's disease. J. Clin. Epidemiol. 55:25-31.
3. de Rijk, M.C., et al. 2000. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 54(Suppl. 5):S21-S23.
4. Goetz, C.G. 2002. Charcot and Parkinson's disease. In Parkinson's disease diagnosis and clinical management. S. Factor and W. Weiner, editors. Demos Medical Publishing. New York, New York, USA. 19-26.
5. Brissaud, E. 1895. Nature et pathogenie de la maladie de Parkinson. In Leçons sur les malades nerveuses. Masson. Paris, France. 488-501.
6. Kapp, W. 1992. The history of drugs for the treatment of Parkinson's disease. J. Neural Transm. Suppl. 38:1-6.
7. Lewy, F.H. 1912. Paralysis agitans. I. Pathologische anatomie. In Handbuch der neurologie. M. Lewandowsky, editor. Springer. Berlin, Germany. 920-933.
8. Greenfield, J.G., and Bosanquet, F.D. 1953. The brain-stem lesions in Parkinsonism. J. Neurol. Neurosurg. Psychiatry. 16:213-226.
9. Ehringer, H., and Hornykiewicz, O. 1960. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) ingerhirn des menschen und ihr verhalten bei erkrankugen des extrapyramidalen systems. Klin. wochenschr. 38:1236-1239.
10. Poirier, L.J., and Sourkes, T.L. 1965. Influence of the substantia nigra on the catecholamine content of the striatum. Brain. 88:181-192.
11. Carlsson, A., Lindqvist, M., and Magnusson, T. 1957. 3,4- Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 180:1200.
12. Cotzias, G.C., Papavasiliou, P.S., and Gellene, R. 1969. Modification of Parkinsonism - chronic treatment with L-dopa. N. Engl. J. Med. 280:337-345.
13. Rinne, U.K., and Sonninen, V. 1973. Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. Arch. Neurol. 28:107-110.
14. Rinne, U.K., Sonninen, V., and Sirtola, T. 1972. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor. Z. Neurol. 202:1-20.
15. Ericsson, A.D. 1971. Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J. Neurol. Sci. 14:193-197.
16. Myllyla, V.V., Sotaniemi, K.A., Illi, A., Suominen, K., and Keranen, T. 1993. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur. J. Clin. Pharmacol. 45:419-423.
17. Roberts, J.W., et al. 1993. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology. 43:2685-2688.
18. Chrisp, P., Mammen, G.J., and Sorkin, E.M. 1991. Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1:228-248.
19. Gopinathan, G., et al. 1981. Lisuride in parkinsonism. Neurology. 31:371-376.
20. Calne, D.B., Teychenne, P.F., Leigh, P.N., Bamji, A.N., and Greenacre, J.K. 1974. Treatment of parkinsonism with bromocriptine. Lancet. 2:1355-1356.
21. Brophy, B.P. 1998. Surgical palliation of dyskinesiae in Parkinson's disease. Stereotact. Funct. Neurosurg. 70:107-113.
22. Bergman, H., Wichmann, T., and DeLong, M.R. 1990. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 249:1436-1438.
23. Benabid, A.L., et al. 2000. Future prospects of brain stimulation. Neurol. Res. 22:237-246.
24. Hughes, A.J., Daniel, S.E., Blankson, S., and Lees, A.J. 1993. A clinicopathologic study of 100 cases of Parkinson's disease. Arch. Neurol. 50:140-148.
25. Pal, P., Samii, A., and Calne, D. 2002. Cardinal features of early Parkinson's disease. In Parkinson's disease: diagnosis and clinical management. S. Factor and W. Weiner, editors. Demos Medical Publishing. New York, New York, USA. 41-56.
26. de Lau, L.M., Koudstaal, P.J., Hofman, A., and Breteler, M.M. 2006. Subjective complaints precede Parkinson disease: the rotterdam study. Arch. Neurol. 63:362-365.
27. Hughes, A.J., Daniel, S.E., Kilford, L., and Lees, A.J. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 55:181-184.
28. Rajput, A.H., Rozdilsky, B., and Rajput, A. 1991. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can. J. Neurol. Sci. 18:275-278.
29. Hughes, A.J., Daniel, S.E., and Lees, A.J. 2001. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 57:1497-1499.
30. Suchowersky, O., et al. 2006. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Neurology. 66:968-975.
31. Marek, K., Jennings, D., and Seibyl, J. 2003. Neuroimaging in Parkinson's disease. In Handbook of Parkinson's disease. 3rd edition. R. Pahwa, K. Lyons, and W. Koller, editors. Marcel Dekker, Inc. New York, New York, USA. 179-202.
32. Van Laere, K., et al. 2006. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J. Nucl. Med. 47:384-392.
33. Berg, D., Hochstrasser, H., Schweitzer, K.J., and Riess, O. 2006. Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox. Res. 9:1-13.
34. Ponsen, M.M., et al. 2004. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann. Neurol. 56:173-181.
35. El-Agnaf, O.M., et al. 2006. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20:419-425.
36. Michell, A.W., Lewis, S.J., Foltynie, T., and Barker, R.A. 2004. Biomarkers and Parkinson's disease. Brain. 127:1693-1705.
37. Ozelius, L.J., et al. 2006. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354:424-425.
38. Lesage, S., et al. 2006. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354:422-423.
39. Braak, H., et al. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24:197-211.
40. Marsden, C. 1983. Neuromelanin and Parkinson's disease. J. Neural Transm. Suppl. 19:121-141.
41. Jellinger, K. 2005. The pathology of parkinson's disease-recent advances. In Scientific basis for the treatment of Parkinson's disease. 2nd edition. N. Galvez-Jimenez, editor. Taylor & Francis. New York, New York, USA/London, United Kingdom. 53-85.
42. Braak, H., de Vos, R.A., Bohl, J., and Del Tredici, K. 2006. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396:67-72.
43. Poskanzer, D.C., and Schwab, R.S. 1963. Cohort analysis of Parkinson's syndrome: evidence for a single etiology related to subclinical infection about 1920. J. Chronic Dis. 16:961-973.
44. Reid, A.H., McCall, S., Henry, J.M., and Taubenberger, J.K. 2001. Experimenting on the past: the enigma of von Economo's encephalitis lethargica. J. Neuropathol. Exp. Neurol. 60:663-670.
45. Burns, R.S., et al. 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 80:4546-4550.
46. Langston, J.W., Ballard, P., Tetrud, J.W., and Irwin, I. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:979-980.
47. McNaught, K.S., Perl, D.P., Brownell, A.L., and Olanow, C.W. 2004. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56:149-162.
48. Betarbet, R., et al. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:1301-1306.
49. Landrigan, P.J., et al. 2005. Early environmental origins of neurodegenerative disease in later life. Environ. Health Perspect. 113:1230-1233.
50. Bell, J., and Clark, A. 1926. A pedigee of paralysis agitans. Ann. Eugen. 1:455-462.
51. Allen, W. 1937. Inheritence of the shaking palsy. Arch. Intern. Med. 60:424-436.
52. Lazzarini, A.M., et al. 1994. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology. 44:499-506.
53. Maraganore, D.M., et al. 2005. High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 77:685-693.
54. Mizuta, I., et al. 2006. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum. Mol. Genet. 15:1151-1158.
55. van der Walt, J.M., et al. 2004. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am. J. Hum. Genet. 74:1121-1127.
56. Le, W.D., et al. 2003. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33:85-89.
57. Polymeropoulos, M.H., et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:2045-2047.
58. Kruger, R., et al. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18:106-108.
59. Zarranz, J.J., et al. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55:164-173.
60. Singleton, A.B., et al. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 302:841.
61. Nishioka, K., et al. 2006. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 59:298-309.
62. Langston, J.W., et al. 1998. Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. Exp. Neurol. 154:684-690.
63. Spira, P.J., Sharpe, D.M., Halliday, G., Cavanagh, J., and Nicholson, G.A. 2001. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49:313-319.
64. Farrer, M., et al. 2004. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55:174-179.
65. Muenter, M.D., et al. 1998. Hereditary form of parkinsonism - dementia. Ann. Neurol. 43:768-781.
66. Eriksen, J.L., Przedborski, S., and Petrucelli, L. 2005. Gene dosage and pathogenesis of Parkinson's disease. Trends Mol. Med. 11:91-96.
67. Pals, P., et al. 2004. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 56:591-595.
68. Hadjigeorgiou, G.M., et al. 2005. Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset. Mov. Disord. 21:534-539.
69. Tan, E.K., et al. 2004. Alpha-synuclein haplotypes implicated in risk of Parkinson's disease. Neurology. 62:128-131.
70. Spillantini, M.G., et al. 1997. Alpha-synuclein in Lewy bodies. Nature. 388:839-840.
71. Dauer, W., et al. 2002. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 99:14524-14529.
72. Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A., and Lansbury, P.T., Jr. 1996. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 35:13709-13715.
73. Hasegawa, M., et al. 2002. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277:49071-49076.
74. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., and Goedert, M. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 95:6469-6473.
75. Moore, D.J., West, A.B., Dawson, V.L., and Dawson, T.M. 2005. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28:57-87.
76. Mizuno, Y., Mochizuki, H., and Hattori, N. 2005. Alpha-synuclein, nigral degeneration and parkinsonism. In Scientific basis for the treatment of Parkinson's disease. 2nd edition. N. Galvez-Jimenez, editor. Taylor & Francis. New York, New York, USA/London, United Kingdom. 87-104.
77. Li, W., et al. 2005. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. U. S. A. 102:2162-2167.
78. Abeliovich, A., et al. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 25:239-252.
79. Jensen, P.H., Li, J.Y., Dahlstrom, A., and Dotti, C.G. 1999. Axonal transport of synucleins is mediated by all rate components. Eur. J. Neurosci. 11:3369-3376.
80. Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N., and Rubinsztein, D.C. 2003. Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278:25009-25013.
81. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O.M., and Sudhof, T.C. 2005. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 123:383-396.
82. Rochet, J.C., et al. 2004. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23:23-34.
83. Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., and Sulzer, D. 2004. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 305:1292-1295.
84. Mukaetova-Ladinska, E.B., and McKeith, I.G. 2006. Pathophysiology of synuclein aggregation in Lewy body disease. Mech. Ageing Dev. 127:188-202.
85. Snyder, H., et al. 2003. Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278:11753-11759.
86. Kitada, T., et al. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 392:605-608.
87. Lohmann, E., et al. 2003. How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol. 54:176-185.
88. Bonifati, V., et al. 2001. The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Neurol. Sci. 22:51-52.
89. Oliveira, S.A., et al. 2003. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann. Neurol. 53:624-629.
90. Khan, N.L., et al. 2005. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology. 64:134-136.
91. Lincoln, S.J., et al. 2003. Parkin variants in North American Parkinson's disease: cases and controls. Mov. Disord. 18:1306-1311.
92. Oliveira, S.A., et al. 2003. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch. Neurol. 60:975-980.
93. Lucking, C.B., et al. 2000. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N. Engl. J. Med. 342:1560-1567.
94. Mori, H., et al. 1998. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology. 51:890-892.
95. Farrer, M., et al. 2001. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50:293-300.
96. Sasaki, S., Shirata, A., Yamane, K., and Iwata, M. 2004. Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions. Neurology. 63:678-682.
97. Zhang, Y., et al. 2000. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U. S. A. 97:13354-13359.
98. Ko, H.S., et al. 2005. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 25:7968-7978.
99. Ko, H.S., Kim, S.W., Sriram, S.R., Dawson, V.L., and Dawson, T.M. 2006. Identification of far up stream element binding protein-1 as an authentic parkin substrate. J. Biol. Chem. doi:10.1074/jbc.C600041200.
100. Oliveira, S.A., et al. 2005. Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease. Am. J. Hum. Genet. 77:252-264.
101. Leroy, E., et al. 1998. The ubiquitin pathway in Parkinson's disease. Nature. 395:451-452.
102. Healy, D.G., et al. 2006. UCHL-1 is not a Parkinson's disease susceptibility gene. Ann. Neurol. 59:627-633.
103. Maraganore, D.M., et al. 2004. UCHL1 is a Parkinson's disease susceptibility gene. Ann. Neurol. 55:512-521.
104. Liu, Y., Fallon, L., Lashuel, H.A., Liu, Z., and Lansbury, P.T., Jr. 2002. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 111:209-218.
105. Lim, K.L., Dawson, V.L., and Dawson, T.M. 2006. Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases? Neurobiol. Aging. 27:524-529.
106. Chung, K.K., et al. 2004. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science. 304:1328-1331.
107. LaVoie, M.J., Ostaszewski, B.L., Weihofen, A., Schlossmacher, M.G., and Selkoe, D.J. 2005. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11:1214-1221.
108. McNaught, K.S., and Jenner, P. 2001. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:191-194.
109. McNaught, K.S., Belizaire, R., Isacson, O., Jenner, P., and Olanow, C.W. 2003. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179:38-46.
110. Bonifati, V., et al. 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 299:256-259.
111. Dekker, M., et al. 2003. Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov. Disord. 18:751-757.
112. Lockhart, P.J., et al. 2004. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function [letter]. J. Med. Genet. 41:e22.
113. Choi, J., et al. 2006. Oxidative damage of DJ-1 is linked to sporadic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 281:10816-10824.
114. Zhang, L., et al. 2005. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14:2063-2073.
115. Moore, D.J., et al. 2005. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14:71-84.
116. Zhou, W., Zhu, M., Wilson, M.A., Petsko, G.A., and Fink, A.L. 2006. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J. Mol. Biol. 356:1036-1048.
117. Kim, R.H., et al. 2005. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 102:5215-5220.
118. Ito, G., Ariga, H., Nakagawa, Y., and Iwatsubo, T. 2006. Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1. Biochem. Biophys. Res. Commun. 339:667-672.
119. Abou-Sleiman, P.M., Muqit, M.M., and Wood, N.W. 2006. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7:207-219.
120. Valente, E.M., et al. 2004. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 304:1158-1160.
121. Li, Y., et al. 2005. Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. Neurology. 64:1955-1957.
122. Klein, C., et al. 2005. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur. J. Hum. Genet. 13:1086-1093.
123. Valente, E.M., et al. 2004. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56:336-341.
124. Ibanez, P., et al. 2006. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain. 129:686-694.
125. Tan, E.K., et al. 2006. PINK1 mutations in sporadic early-onset Parkinson's disease. Mov. Disord. doi:10.1002/mds.20810.